Research Topics
Species | Parinda MehtaSummaryAffiliation: Cincinnati Children's Hospital Medical Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Pharmacogenetics of acute lymphoblastic leukemiaParinda A Mehta
Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229, USA
Curr Opin Hematol 11:434-8. 2004..This review discusses literature reports in this area and describes some of the challenges facing the field as it moves forward...
Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic studyParinda A Mehta
Division of Bone Marrow Transplantation Immune Deficiency, Cancer and Blood Diseases Institute, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229, USA
Biol Blood Marrow Transplant 16:1458-62. 2010..These data suggest that alternate day micafungin dosing, as described here, may provide an attractive alternative for antifungal prophylaxis in HSCT patients and merits further evaluation...- Numerical chromosomal changes and risk of development of myelodysplastic syndrome--acute myeloid leukemia in patients with Fanconi anemiaParinda A Mehta
Division of Bone Marrow Transplantation and Immune Deficiency, Cancer and Blood Diseases Institute, Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45229, USA
Cancer Genet Cytogenet 203:180-6. 2010.... 
FAS promoter polymorphism: outcome of childhood acute myeloid leukemia. A children's oncology group reportParinda A Mehta
Division of Hematology Oncology, Cincinnati Children s Hospital and Medical Center, Cincinnati, Ohio 45229, USA
Clin Cancer Res 14:7896-9. 2008..We hypothesized that FAS genotype by altering susceptibility to apoptosis might affect outcome of childhood AML therapy...- Allogeneic transplantation for childhood ALLP A Mehta
Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA
Bone Marrow Transplant 41:133-9. 2008..This review focuses on the appropriate use of transplantation for children with ALL and optimization of transplant procedures to improve survival and reduce late consequences of therapy... - Interleukin-1 alpha genotype and outcome of unrelated donor haematopoietic stem cell transplantation for chronic myeloid leukaemiaParinda A Mehta
Division of Haematology Oncology, Cincinnati Children s Hospital and Medical Center, Cincinnati, OH 45229, USA
Br J Haematol 137:152-7. 2007..We did not observe an association with IL-1alpha genotype in donor and/or recipient and transplant-outcome. These data suggest that the outcome of unrelated donor transplant for CML is not influenced by IL-1alpha genotype... - Pre-transplant minimal residual disease in children with acute lymphoblastic leukemiaParinda A Mehta
Division of Hematology/Oncology, Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
Pediatr Blood Cancer 48:1-2. 2007 - Chemotherapy for myeloid malignancy in children with Fanconi anemiaParinda A Mehta
Fanconi Anemia Comprehensive Care Center, Cincinnati Children s Hospital Medical Center CCHMC, Cincinnati, Ohio 45229, USA
Pediatr Blood Cancer 48:668-72. 2007..In this report we describe the toxicity of a chemotherapy approach for patients with FA and myeloid malignancy to achieve cytoreduction prior to SCT... - High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic studyParinda Mehta
Division of Hematology Oncology and PPRU, Cincinnati Children s Hospital Medical Center, Department of Pediatrics, University of Cincinnati, Cincinnati, Ohio 45229, USA
Biol Blood Marrow Transplant 12:235-40. 2006..Our data show measurable amphotericin B plasma concentrations 7 days after high-dose infusion of AmBisome. This suggests that once-weekly dosing, as described in this study, may provide useful protection against fungal infections... - XPD Lys751Gln polymorphism in the etiology and outcome of childhood acute myeloid leukemia: a Children's Oncology Group reportParinda A Mehta
Cincinnati Children s Hospital and Medical Center, 3333 Burnet Ave, Cincinnati, OH 45229, USA
Blood 107:39-45. 2006..These data, representing the only data in pediatric AML, suggest that XPD genotype does not affect the etiology or outcome of childhood AML... - Pediatric acute lymphoblastic leukemia: is there still a role for transplant?Stella M Davies
Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45230, USA
Hematology Am Soc Hematol Educ Program 2010:363-7. 2010..However, a rigorous approach must be taken in determining whether transplant does improve outcome whenever this strategy is applied... - Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantationRebecca A Marsh
Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45229, USA
Blood 116:5824-31. 2010..0001). We conclude that RIC significantly improves the outcome of patients with HLH undergoing allogeneic HCT... - The FA pathway counteracts oxidative stress through selective protection of antioxidant defense gene promotersWei Du
Divisions of Experimental Hematology and Cancer Biology, Cincinnati Children s Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH 45229, USA
Blood 119:4142-51. 2012..In addition, oxidative stress-induced FANCD2 ubiquitination is required for the formation of a FA-BRG1-promoter complex. Taken together, these data identify a role for the FA pathway in cellular antioxidant defense... - Bone marrow transplantation for inherited bone marrow failure syndromesParinda Mehta
Cincinnati Children s Hospital Medical Center and the University of Cincinnati College of Medicine, 3333 Burnet Avenue, Cincinnati, OH 45229, USA
Pediatr Clin North Am 57:147-70. 2010..The rarity of these diseases coupled with the far more likely incremental improvements that will result from ongoing research will require prospective international clinical trials to improve the outcome for these children... - Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemiaDeepika Bhatla
Division of Hematology Oncology, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, USA
Br J Haematol 144:388-94. 2009..59 +/- 12% AA and 55 +/- 14% AC; P = 0.40). These data indicate that children with a low activity CDA genotype are at increased risk of TRM with ara-C based therapy for AML...